Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04058353
Other study ID # VX18-445-104
Secondary ID 2018-002835-76
Status Completed
Phase Phase 3
First received
Last updated
Start date August 28, 2019
Est. completion date June 12, 2020

Study information

Verified date June 2021
Source Vertex Pharmaceuticals Incorporated
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy, safety and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a gating or residual function mutation (F/G and F/RF genotypes).


Recruitment information / eligibility

Status Completed
Enrollment 271
Est. completion date June 12, 2020
Est. primary completion date June 12, 2020
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Key Inclusion Criteria: - Subject has a confirmed diagnosis of CF and is heterozygous for F508del and either a gating or residual function mutation (F/G and F/RF genotypes) - Forced expiratory volume in 1 second (FEV1) value =40% and =90% of predicted mean for age, sex, and height Key Exclusion Criteria: - Clinically significant cirrhosis with or without portal hypertension - Lung infection with organisms associated with a more rapid decline in pulmonary status - Solid organ or hematological transplantation Other protocol defined Inclusion/Exclusion criteria may apply

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ELX/TEZ/IVA
FDC tablet for oral administration.
IVA
Mono-tablet for oral administration.
TEZ/IVA
Fixed-dose combination (FDC) tablet for oral administration.

Locations

Country Name City State
Australia The Prince Charles Hospital Chermside
Australia Alfred Hospital Melbourne, VIC
Australia Perth Children's Hospital Nedlands
Australia The Royal Children's Hospital Parkville, VIC
Australia Mater Adult Hospital South Brisbane
Australia Queensland Children's Hospital South Brisbane
Australia Westmead Hospital Westmead
Belgium Cliniques Universitaires de Bruxelles Hopital Erasme Brussels
Belgium Universitair Ziekenhuis Brussel - Campus Jette Brussels
Belgium Universitair Ziekenhuis Gent Gent
Belgium Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg Leuven
Canada Stollery Children's Hospital Edmonton
Canada McGill University Health Center Québec
Canada St. Michael's Hospital Toronto
Canada St. Paul's Hospital Vancouver
Denmark Juliane Marie Center, Rigshospitalet Copenhagen
France Centre Hospitalier Lyon Sud Benite Cedex
France Groupe Hospitaler Pellegrin, CHU De Bordeaux Bordeaux cedex
France CHRU de Lille - Hopital Albert Calmette Lille
France CHU Marseille - Hopital Nord Marseille
France CHU de Montpellier - Hopital Arnaud de Villeneuve Montpellier Cedex 5
France Hopital Cochin Paris
France Hopital Necker, Enfants Malades Paris Cedex 15
France Hopital Pontchaillou CHU de Rennes Rennes Cedex
Germany Charite Paediatric Pulmonology Department Berlin
Germany Friedrich-Alexander University of Erlangen-Nuremberg, University Children's Hospital Erlangen
Germany Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen Essen
Germany Justus-Liebig-Universitaet Gießen Zentrum fur Kinderheilkunde und Jugendmedizin Giessen
Germany Universitätsklinikum Halle (Saale) / Universitätsklinik und Poliklinik für Innere Medizin, Schwerpunkt Pneumologie Halle
Germany Pneumologisches Studienzentrum Muenchen-West Muenchen
Germany University Hospital Wuerzburg Würzburg
Ireland Cork University Hospital Cork
Ireland Beaumont Hospital Dublin
Ireland St. Vincent's University Hospital Dublin
Israel University Hospital Limerick (Adults) Limerick
Italy Azienda Ospedaliero Universitaria Ospedale Riuniti Ancona
Italy IRCCS Istituto Giannina Gaslini-Ospedale Pediatrico Genova
Italy Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano
Italy Malattie Apparato Respiratorio 2 - Fibrosi Cistica Orbassano
Italy Ospedale Pediatrico Bambino Gesu Rome
Italy Azienda Ospedaliera di Verona-Ospedale Civile Maggiore Verona
Netherlands HagaZiekenhuis van den Haag Den Haag
Netherlands University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis Heidelberglaan
Netherlands UMC St. Radboud Nijmegen
Spain Hospital Universitari Vall d´Hebron Servicio de Broncoscopia Barcelona
Spain Hospital Virgen de la Arrixaca Murcia
Spain Hospital Universitario Virgen del Rocio Sevilla
Spain Hospital Universitario y Politecnico La Fe Valencia
United Kingdom Papworth Hospital NHS Foundation Trust, Papworth Everard Cambridge
United Kingdom Royal Devon and Exeter NHS Foundation Trust, Royal Devon and Exeter Hospital Exeter
United Kingdom Clinical Research Facility, Queen Elizabeth University Hospital Glasgow
United Kingdom St. James University Hospital Leeds
United Kingdom Liverpool Heart and Chest Hospital Liverpool
United Kingdom Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital London
United Kingdom Wythenshawe Hospital Manchester
United Kingdom Southampton General Hospital Southampton
United States Michigan Medicine Ann Arbor Michigan
United States Dell Children's Medical Group Austin Texas
United States University of Alabama at Birmingham Birmingham Alabama
United States Boston Children's Hospital Boston Massachusetts
United States Massachusetts General Hospital Cystic Fibrosis Center Clinical Rsearch Center Boston Massachusetts
United States University of North Carolina Hospitals Chapel Hill North Carolina
United States UC Health Holmes Cincinnati Ohio
United States Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center Cleveland Ohio
United States Nationwide Children's Hospital Columbus Ohio
United States The University of Texas Southwestern Medical Center Dallas Texas
United States National Jewish Health Denver Colorado
United States Texas Children's Hospital Houston Texas
United States Indiana University Indianapolis Indiana
United States The University of Iowa Hospitals and Clinics Iowa City Iowa
United States University of Kansas Medical Center Kansas City Kansas
United States Dartmouth Hitchcock Medical Center Lebanon New Hampshire
United States University of Kentucky Lexington Kentucky
United States Miller Children's Hospital / Long Beach Memorial Long Beach California
United States University of Wisconsin Hospital and Clinics Madison Wisconsin
United States University of Miami Miller School of Medicine Miami Florida
United States University of Minnesota Minneapolis Minnesota
United States Northwell Health- Long Island Jewish Medical Center New Hyde Park New York
United States Columbia University Medical Center New York New York
United States Mount Sinai Beth Israel New York New York
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States Central Florida Pulmonary Group, PA Orlando Florida
United States Stanford University Palo Alto California
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania
United States Oregon Health & Science University Portland Oregon
United States University of California Davis Medical Center Sacramento California
United States Washington University School of Medicine / St. Louis Children's Hospital Saint Louis Missouri
United States University of Utah / Primary Children's Medical Center Salt Lake City Utah
United States University of California San Francisco, Lung Transplant Program San Francisco California
United States University of Washington Medical Center Seattle Washington
United States ProMedica Toledo Hospital/Toledo Children's Hospital/Pediatric Pulmonary & Cystic Fibrosis Center Toledo Ohio
United States Banner University of Arizona Medical Center Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
Vertex Pharmaceuticals Incorporated

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Canada,  Denmark,  France,  Germany,  Ireland,  Israel,  Italy,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for ELX/TEZ/IVA Group FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. From Baseline Through Week 8
Secondary Absolute Change in Sweat Chloride (SwCl) for ELX/TEZ/IVA Group Sweat samples were collected using an approved collection device. From Baseline Through Week 8
Secondary Absolute Change in ppFEV1 for the ELX/TEZ/IVA Group Compared to the Control Group FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. From Baseline Through Week 8
Secondary Absolute Change in SwCl for ELX/TEZ/IVA Group Compared to the Control Group Sweat samples were collected using an approved collection device. From Baseline Through Week 8
Secondary Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for ELX/TEZ/IVA Group The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. From Baseline Through Week 8
Secondary Absolute Change in CFQ-R Respiratory Domain Score for ELX/TEZ/IVA Group Compared to the Control Group The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. From Baseline Through Week 8
Secondary Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Day 1 up to Week 12
See also
  Status Clinical Trial Phase
Completed NCT04696198 - Thoracic Mobility in Cystic Fibrosis Care N/A
Completed NCT00803205 - Study of Ataluren (PTC124™) in Cystic Fibrosis Phase 3
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03601637 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Phase 3
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting NCT06030206 - Lung Transplant READY CF 2: A Multi-site RCT N/A
Recruiting NCT06012084 - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis N/A
Recruiting NCT06032273 - Lung Transplant READY CF 2: CARING CF Ancillary RCT N/A
Recruiting NCT05392855 - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) N/A
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition Phase 2/Phase 3
Recruiting NCT04056702 - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Completed NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed NCT04058548 - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation N/A
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Recruiting NCT03506061 - Trikafta in Cystic Fibrosis Patients Phase 2
Completed NCT03566550 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting NCT04010253 - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis N/A